Form 4: Alaunos Therapeutics Director and 10% Owner Robert Postma Increases Stake Through Stock and Convertible Preferred Acquisitions

Robert W. Postma, a Director and 10% owner of Alaunos Therapeutics, Inc., has reported significant acquisitions of common stock and convertible preferred stock, increasing his beneficial ownership in the company.

Summary

• Robert W. Postma, a Director and 10% Owner of Alaunos Therapeutics, Inc. (TCRT), reported several transactions increasing his beneficial ownership.
• On April 11, 2025, Mr. Postma, through WaterMill Asset Management Corp., acquired 500 shares of Series A-1 Convertible Preferred Stock, convertible into 181,159 shares of Common Stock at a conversion price of $2.76.
• On April 13, 2025, Mr. Postma acquired 20,804 shares of Common Stock at a price of $2.92 per share.
• On June 24, 2025, Mr. Postma, through WaterMill Asset Management Corp., acquired 600 shares of Series A-2 Convertible Preferred Stock, convertible into 133,630.29 shares of Common Stock at a conversion price of $4.49.
• Following these transactions, his direct beneficial ownership of Common Stock is 29,083 shares.
• He also holds indirect beneficial ownership of 24 Common Stock shares via his spouse's IRA and 33,333 Common Stock shares via WaterMill Asset Management Corp., where he serves as principal.
• Additionally, Mr. Postma holds an Employee Stock Option to buy 3,737 Common Stock shares at an exercise price of $10.3, which vests monthly starting June 6, 2024, with any unvested amount vesting before the Company's 2025 annual general meeting, and expires on June 5, 2034.
• The reporting person disclaims beneficial ownership of equity securities from preferred stock conversion if it would result in aggregate ownership exceeding 4.99% of outstanding shares immediately after conversion or issuance.

Sentiment

Score: 8

Explanation: The acquisition of common stock and convertible preferred stock by a director and 10% owner signals strong insider confidence in the company's future prospects and current valuation. This is generally viewed very positively by the market.

Positives

• A Director and 10% owner, Robert W. Postma, has increased his stake in Alaunos Therapeutics through direct common stock purchases and acquisitions of convertible preferred stock, signaling strong insider confidence.
• The acquisition of common stock at $2.92 per share and convertible preferred stock at conversion prices of $2.76 and $4.49 indicates management's belief in the company's current valuation and future prospects.
• The long-term vesting schedule for the employee stock option, extending through 2025 and expiring in 2034, aligns the director's interests with sustained shareholder value.

Risks

• The reporting person disclaims beneficial ownership of common stock derived from preferred stock conversion if it would exceed 4.99% of outstanding shares, which could imply a potential for future dilution if the preferred stock is fully converted and the ownership threshold is not met.
• The value of the acquired common stock and convertible preferred stock is subject to market fluctuations and the inherent risks associated with equity investments.

Future Outlook

The document indicates a long-term commitment from a key insider, with stock options vesting through 2025 and expiring in 2034, suggesting a belief in the company's sustained future performance.

Management Comments

• "The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance."

Industry Context

This insider buying activity by a director and significant shareholder in a biotechnology company like Alaunos Therapeutics (TCRT) can be interpreted by the market as a positive signal, especially in the often volatile biotech sector where investor confidence in management's long-term vision is crucial. It suggests that a key insider believes the company's current valuation is attractive and its future prospects are strong, potentially indicating upcoming positive developments or a belief in the company's strategic direction.

Related Party Transactions

• The acquisition of Series A-1 and Series A-2 Convertible Preferred Stock, as well as a portion of the Common Stock, was made indirectly through WaterMill Asset Management Corp., where the reporting person, Robert W. Postma, serves as the principal.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The vesting schedule of the employee stock option aligns the director's long-term interests with the company's performance, benefiting all stakeholders.

Next Steps

• Continued vesting of the Employee Stock Option on a monthly basis until the Company's 2025 annual general meeting of stockholders.
• Potential conversion of Series A-1 and Series A-2 Convertible Preferred Stock into Common Stock, subject to the 4.99% beneficial ownership limitation.

Key Dates

Recommendation

Keywords

Alaunos Therapeutics, TCRT, SEC Form 4, Insider Trading, Beneficial Ownership, Director Stock Purchase, Convertible Preferred Stock, Employee Stock Option, Robert W. Postma, WaterMill Asset Management Corp.